Below are the financial statements of Glenmark Pharmaceuticals, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of INR | 2025 as of 2025-03-31 | 2024 as of 2024-03-31 |
|---|---|---|
| Assets | — | — |
| Non-current assets | — | — |
| Property, plant and equipment | 30,761.59a | 29,190.77a |
| Capital work-in-progress | 5,419.87a | 4,193.24a |
| Right-of-use assets | 2,432.07a | 1,990.76a |
| Goodwill | 702.66a | 673.59a |
| Other intangible assets | 10,971.93a | 10,246.5a |
| Intangible assets under development | 2,928.4a | 2,425.56a |
| Financial assets | — | — |
| Investments | 563.55a | 7,896.64a |
| Other financial assets | 729.42a | 698.83a |
| Deferred tax assets (net) | 11,241.09a | 10,497.22a |
| Other non-current assets | 1,790.31a | 1,492.31a |
| Total non-current assets | 67,540.89a | 69,305.42a |
| Current assets | — | — |
| Inventories | 30,285.3a | 25,130.51a |
| Financial assets | — | — |
| Trade receivables | 33,419.47a | 18,584.12a |
| Cash and cash equivalents | 16,757.07a | 16,582.7a |
| Bank balances other than cash and cash equivalents | 295.21a | 11.86a |
| Other financial assets | 624.46a | 1,735.97a |
| Other current assets | 11,573.14a | 12,235.66a |
| Total current assets | 92,954.65a | 74,280.82a |
| Total assets | 160,495.54a | 143,586.24a |
| Equity | — | — |
| Equity share capital | 282.19a | 282.19a |
| Other equity | 88,212.22a | 78,197.08a |
| Equity attributable to owners of Glenmark Pharmaceuticals Limited | 88,494.41a | 78,479.27a |
| Non-controlling interests | -3.71a | -3.8a |
| Total equity | 88,490.7a | 78,475.47a |
| Liabilities | — | — |
| Non-current liabilities | — | — |
| Financial liabilities | — | — |
| Borrowings | 5,127a | 0a |
| Lease liabilities | 1,862.1a | 1,516.91a |
| Other non-current financial liabilities | 4,759.62a | 5,388.28a |
| Deferred tax liabilities (net) | 585.88a | 2.8a |
| Other non-current liabilities | 0a | 16.91a |
| Total non-current liabilities | 12,334.6a | 6,924.9a |
| Current liabilities | — | — |
| Financial liabilities | — | — |
| Borrowings | 16,814.95a | 9,905.96a |
| Lease liabilities | 922.62a | 886.43a |
| Trade payables | — | — |
| Total outstanding dues of Micro enterprises and Small enterprises | 214.41a | 173.32a |
| Total outstanding dues of other than Micro enterprises and Small enterprises | 25,580.89a | 25,185.93a |
| Other current financial liabilities | 7,902.82a | 10,269.84a |
| Other current liabilities | 1,989.98a | 2,443.63a |
| Provisions | 5,960.83a | 6,411.24a |
| Current tax liabilities (net) | 283.74a | 2,909.52a |
| Total current liabilities | 59,670.24a | 58,185.87a |
| Total liabilities | 72,004.84a | 65,110.77a |
| Equity and liabilities | — | — |
| Total equity and liabilities | 160,495.54a | 143,586.24a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Glenmark Pharmaceuticals’s data sources below and access millions more through our Disclosure Search.